Company Overview
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -91.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -10.62% |
| 1 Year: | -91.87% |
Stock Price Performance
| 1 Year: | -75.65% |
| 6 Months: | -80.05% |
| 3 Months: | -82.66% |
| 1 Month: | -26.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.34 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -10.6% CAGR over 5 years.
- Trading 84.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELTX Elicio Therapeutics, Inc. PHARMA | 2.35 | -1.09 | $61.76M | 0.00% | - | - | -10.62% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 865.00K | 729.00K | 827.00K | 371.00K | 540.00K | 1.46M | 1.65M | 653.00K | 0 | 0 | - | - | - | - | - | - | - | - | - |
| Operating Income | -12.57M | -17.27M | -11.59M | -19.94M | -18.24M | -15.76M | -14.48M | -6.23M | -5.77M | -7.80M | -7.78M | -10.77M | -10.24M | -10.92M | -10.34M | -10.74M | -10.09M | -8.04M | -10.60M |
| Net Income | -13.22M | -20.34M | -17.67M | -36.69M | -17.07M | -15.70M | -7.06M | -7.30M | -7.20M | -8.03M | -7.56M | -10.66M | -11.83M | -7.23M | -18.84M | -11.21M | -10.56M | -10.08M | -11.82M |
| Diluted EPS | -0.91 | -1.40 | -1.19 | -1.56 | -0.58 | -0.53 | -0.48 | -23.20 | -22.67 | -24.77 | -2.61 | -1.27 | -1.15 | -0.64 | -1.39 | -0.87 | -0.66 | -0.60 | -0.65 |
| R&D Expense | 9.60M | 12.23M | 6.09M | 14.30M | 14.44M | 13.29M | 11.67M | 5.04M | 4.59M | 5.48M | 4.94M | 7.26M | 7.56M | 8.18M | 7.21M | 7.78M | 7.01M | 5.04M | 6.76M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.88M | 28.31M | 2.30M | - | - | - |
| Operating Income | -55.27M | -39.31M | -23.73M | -35.74M | -44.99M | -37.71M |
| Net Income | -80.11M | -54.57M | -28.21M | -35.20M | -51.90M | -39.57M |
| Diluted EPS | -5.43 | -1.93 | -89.27 | -6.96 | -4.25 | -2.58 |
| R&D Expense | 38.98M | 48.70M | 18.10M | 23.85M | 33.66M | 24.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 47.35M | 96.51M | 22.66M | 27.15M | 28.18M | 25.86M |
| Total Equity | -18.59M | -90.45M | -74.54M | -102.14M | 11.37M | -11.31M | 1.64M |
| Cash & Equivalents | - | 34.61M | 88.76M | 6.16M | 12.89M | 17.62M | 18.56M |
| Long Term Debt | - | 635.00K | 0 | - | - | 20.03M | 9.41M |
| Total Liabilities | - | 137.80M | 15.01M | 13.75M | 15.77M | 39.49M | 24.23M |
| Current Liabilities | - | 107.45M | 11.30M | 6.87M | 9.76M | 11.52M | 8.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.89M | - | -22.18M | -32.69M | -37.07M | -36.95M |
| Investing Cash Flow | -41.00K | - | -654.00K | -32.00K | -84.00K | -16.00K |
| Financing Cash Flow | 52.41M | - | 21.20M | 38.61M | 42.32M | 36.70M |
| Capital Expenditure | -41.00K | - | -654.00K | -66.00K | -87.00K | -16.00K |
| Free Cash Flow | -22.93M | - | -22.83M | -32.76M | -37.16M | -36.97M |
| Net Change in Cash | - | - | -1.63M | 5.89M | 5.17M | -273.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -1,919.2% | -138.8% | -1,031.4% | - | - | - |
| Net Margin % | -2,781.5% | -192.8% | -1,225.9% | - | - | - |
| ROE % | 88.6% | 73.2% | 27.6% | -309.5% | 458.8% | -2,418.8% |
| ROCE % | 92.0% | -46.1% | -150.2% | -205.5% | -270.1% | -212.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Knoll Capital Management, LLC | 4.61% | 1.21M | $2.29M |
| 2 | Blackrock Inc. | 2.91% | 766.00K | $1.45M |
| 3 | Vanguard Capital Management LLC | 2.18% | 572.15K | $1.08M |
| 4 | Geode Capital Management, LLC | 1.18% | 311.35K | $588.46K |
| 5 | State Street Corporation | 0.68% | 179.42K | $339.10K |
| 6 | Northern Trust Corporation | 0.50% | 130.16K | $246.01K |
| 7 | Ikarian Capital, LLC | 0.38% | 100.00K | $189.00K |
| 8 | Vanguard Portfolio Management LLC | 0.34% | 88.91K | $168.03K |
| 9 | Vanguard Fiduciary Trust Co | 0.34% | 88.06K | $166.44K |
| 10 | Alliancebernstein L.P. | 0.31% | 81.28K | $153.62K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELTX
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQbG9LNmJ4M2xJcWlUam45M2N1MXQ2UGpFUUNOdm1oSVlteFI4UTl6Q0FOOHd5c1pLM3NFRmxRSjliWkRiUExuODVmbF95c2M3el9BXzlHWktlWm1ZcmJDcEYydHVNM0N0WHFITVZpbFRMcTlJak5pT09VMWVpR0NHR0JZWVB2b1Q3dXpuRl…
Director at Elicio Therapeutics (ELTX) gets 10-year stock option grant - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTFJYWGpsNDZtZ3U0cUNOR1V5aGtFaFk2elUzcnZxazdPdHp2cTdjdE9VV0Nlc1pmbHVJRU1PQ00yVl9FajRiWjEyWk51S0RMeXVlc1R4UDR5b1UtNHM4WmdkZGZSN09Zc2lZT2JnODZJZ2Z4VUZ0NlZXam1OVG1oWHVoSGhSaElRd29RUS…
Why Is ELTX Stock Falling Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPa1RWVUhFdUEwbWpBVngtcDdhMmVuRHdhakxvcDRVcVZaZUJXWWk1STZxU0cyR2hLUE00blliOVhxbUNtVzc2d295MzQ5VGJVaUNub0FQa21iZ3VkZTlCU2FhNWMzUmFrY2F1djVOb2p5RmhXaHNUODVzVE96eGxqSVU3X0NFQWZjaThxNz…
Elicio Therapeutics Reports Inducement Grants - Elicio Therapeutics
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNRWUySTF3WnRHaW40eV92Vk5ldTRtVHpicmJvZzcydDhZbVJveEJ4a0lTTm9MZWVIRElfNVVQcURZUnJiWmZKajV0TVBrajNUakU0WklDZHBLaDJoamtrbGhyMlhtdU9La3Z0UF94VkJwbjg1QjJjUjNoSjJ0SURVZmkydnVPRGJOckE?oc…
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxOOENYWWZWdExrd2hDWWQ2eGViYzJvblNybWhPc0VSY2RjQlRjUkhYQVExdnU3QjBXUFNSRk1tVnBqTXN2am5KLXQ0eG9nemV3dng4b0I2NHNPc1B1bHB1TFZzQzBpVjc3R0dIcF9LT2lYcEo4dmlubVZRWW85TGpfMHc2T19UY2cyLS16ZT…
Elicio Therapeutics (ELTX) Is Down 69.9% After Phase 2 ELI-002 Miss in Pancreatic Cancer Trial - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPYV9BLW8xVFAwQnpkU1dwOW1mRDVtNU5QZ2hVZ094U21tcTVwSVdpQjZLZUxFOElKWXh1bWcxMW9rajFndjhKaVJIQU04aEtFYS1HaHlkbjN4b2QtRUo5RkUxbS1abnVFZTBEQXc3ZDZCaGVHRFRTLUZMMEstWjY4RnNndkhiLWZ3THo2OW…
ELTX — Frequently Asked Questions
What is the current share price of Elicio Therapeutics, Inc. (ELTX)?
As of 2026-09-19 21:16 PDT, Elicio Therapeutics, Inc. (ELTX) trades at $2.35 on NasdaqCM. Its 52-week range is $2.35 to $14.85.
What is the market capitalisation of ELTX?
Elicio Therapeutics, Inc. (ELTX) has a market capitalisation of $61.76M on NasdaqCM.
What is the P/E ratio of ELTX?
ELTX trades at a trailing price-to-earnings (P/E) ratio of -1.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.02.
Is ELTX a good stock to buy?
This page provides a data-driven analysis of Elicio Therapeutics, Inc. (ELTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.